SGLT‐2 Inhibitor Renal Outcome Modification in Type‐2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk
(2020)
Journal Article
Schernthaner, G., Groop, P.-H., Kalra, P. A., Ronco, C., & Taal, M. W. (2020). SGLT‐2 Inhibitor Renal Outcome Modification in Type‐2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk. Diabetes, Obesity and Metabolism, 22(7), 1024-1034. https://doi.org/10.1111/dom.13994
Data from three completed cardiovascular outcome trials (CVOTs), EMPA‐REG OUTCOME, CANVAS Program and DECLARE‐TIMI 58, add to the evidence supporting the potential renoprotective effects of sodium‐glucose linked transporter‐2 (SGLT2) inhibitors in pa... Read More about SGLT‐2 Inhibitor Renal Outcome Modification in Type‐2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk.